Navigation Links
NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
Date:10/6/2009

SAN DIEGO, Oct. 6 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced details today relating to its third quarter 2009 earnings announcement, which will take place on Tuesday, October 20, 2009, after the close of the market.

NuVasive will hold a conference call on Tuesday, October 20, 2009, at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com.

After the live webcast, the call will remain available on NuVasive's website, www.nuvasive.com, through November 20, 2009. In addition, a telephonic replay of the call will be available until November 3, 2009. The replay dial-in numbers are 1-877-660-6853 for domestic callers and 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 331825.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines four categories of products that collectively minimize
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NuVasive to Present at the JMP Securities Healthcare Focus Conference
2. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
3. BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call
4. BD Announces FDA 510(k) Clearance of BD Vacutainer(R) Rapid Serum Blood Collection Tube
5. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
6. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
7. Hill-Rom Announces Corporate Governance Enhancements
8. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
9. Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity
10. Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Covered Stents
11. Accumetrics Announces $16.5M in New Capital Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014   What:   ... present data from a Phase I clinical trial of ... stop Parkinson,s disease progression. The Michael J. Fox Foundation ... will discuss the impact of the results for patients ... July 31, 2014         ...
(Date:7/29/2014)... 29, 2014  Drug development for hepatitis C ... rates and the intense need for curative therapy ... is underway as the market moves away from ... easily-tolerated, interferon-free oral therapies. Logo ... mega blockbuster Sovaldi is the first of these ...
(Date:7/29/2014)... RESEARCH TRIANGLE PARK, N.C. , July 29, ... focused on cloud-based drug design and development, announced ... I grant from the National Science Foundation Small ... is valued at $150,000. Cloud ... accelerates the development process by implementing new, innovative ...
Breaking Medicine Technology:Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000 2
... (NASDAQ: SVA ), a leading provider of biopharmaceutical ... Lee as a director to the Board of the Company ... who resigned from the Board due to personal reasons. ... a leading growth capital fund focused on China and India. ...
... The Neuroblastoma and Medulloblastoma Translational Research Consortium ... genomic-based clinical trial to treat and study pediatric ... The 11-member NMTRC, housed at Van ... of pediatric cancer clinical trial sites that includes ...
Cached Medicine Technology:Sinovac Appoints Kenneth Lee to Board of Directors 2Consortium Opens Landmark Personalized Medicine Children's Cancer Trial 2
(Date:7/29/2014)... California (PRWEB) July 29, 2014 A ... Sciences Professor Doug Ethell, PhD, has developed a blood ... earlier detection and the development of Alzheimer’s disease interventions, ... “Alzheimer’s disease is a puzzle, and this study represents ... for us over the past couple of years,” Ethell ...
(Date:7/29/2014)... July 29, 2014 Most people want to ... younger and feel better about their appearance. There are ... too in Asheville, NC that can help them to look ... salon specializing in result oriented anti-aging procedures that are noninvasive ... problem so many have with cellulite. To accommodate, they ...
(Date:7/29/2014)... way to cure most cases of cancer is to ... approach, however, is that the surgeon may fail to ... , With a new technique, researchers at the University ... surgeons see the entire tumor in the patient, increasing ... on an injectable dye that accumulates in cancerous tissues ...
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market by Type ... & Others), by Application (Oil & Gas, Chemical, CSP, ... & Forecasts to 2019” defines and segments the global ... of the global consumption in terms of volume and ... spread through 199 page sand in-depth TOC on"Heat Transfer ...
(Date:7/29/2014)... As testosterone treatment lawsuits ( http://www.injurybeacon.com/testosterone-androgel/lawsuit/ ... LLP notes that a new study is questioning the ... diabetes. The research, which was published online by The ... involved 88 men who suffered from Type 2 diabetes, ... symptoms and erectile dysfunction. Roughly half of the study ...
Breaking Medicine News(10 mins):Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Supreme Skin Announces Plans for a Grand Re-opening for Their Noninvasive Anti Aging Microcurrent Face and Body Treatments In Asheville, NC 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4
... of Minnesota cancer surgeon and researcher has found a ... the earliest stage of breast cancer choosing to have ... prophylactic mastectomy (CPM) surgery among U.S. women with ductal ... 1998 and 2005, according to Todd Tuttle, M.D., lead ...
... out and destroys tumor cells, researchers say , , FRIDAY, ... virus can target and kill breast cancer stem cells, ... be effective against cancer stem cells, because we have ... cancer cells," Dr. Patrick Lee, a cancer researcher at ...
... Case Timer Solves Widespread ProblemST. LOUIS, April 10 There ... and children are the fastest growing segment. The contact ... growing under those lenses. , , ... fusarium keratitis and acanthamoeba keratitis. These are nasty words ...
... has been promoted to the position of Service Area ... Baron Center, Inc (BCI). Dr. Tau is a ... forensic psychology. Dr. Tau is an expert in assessing ... has been extensively used as a workplace violence and ...
... [Brown University] Nursing homes serving primarily Hispanic ... whose patients were mostly white, according to Brown ... Journal of the American Medical Directors Association ... at the rate of bed sores at nursing ...
... and critical care specialists at Johns Hopkins have begun to ... intensive care unit (ICU) that leads so many patients to ... study reported online April 10 in Critical Care Medicine ... depression six months after hospitalization among very sick ICU patients, ...
Cached Medicine News:Health News:More women with early stage breast cancer choosing double mastectomies 2Health News:Harmless Virus May Be Deadly to Breast Cancer 2Health News:70% of Contact Lens Cases are Contaminated and Nearly 1 in 4 are Never Replaced - a Serious Problem Eye Doctors Want Fixed, WatchDog Group Reports 2Health News:70% of Contact Lens Cases are Contaminated and Nearly 1 in 4 are Never Replaced - a Serious Problem Eye Doctors Want Fixed, WatchDog Group Reports 3Health News:Manny Tau, Psy.D. Promoted to Service Area Leader for the Problematic Behaviors Service Area at Baron Center, Inc 2Health News:Hispanics appear to face poorer quality nursing home care 2Health News:In the ICU, use of benzodiazepines, other factors may predict severity of post-stay depression 2
High-quality eyecare from the preferred name in diagnostic instruments....
Our 2.5v Streak Retinoscope Sets feature instruments with bright light, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: